Immediate early response gene 5-like protein (IER5L)

Immediate early response gene 5-like protein (IER5L) is a cell cycle-regulated member of the immediate-early response gene family, homologous with IER2 and IER5, and is notable for its interaction with the B55 regulatory subunit of protein phosphatase 2A (PP2A). The protein is rapidly targeted for degradation under normal conditions but is consistently upregulated in various malignancies, including NSCLC, prostate cancer, glioblastoma, and colorectal cancer. Research shows that silencing IER5L in cancer models reduces cell migration, invasion, tumor growth, and metastatic potential. Further, IER5L expression correlates with poor prognosis, increased regulatory T cell and neutrophil infiltration, deregulation of ion transport, and altered cell cycle pathways. These findings support its utility as a biomarker and potential target in cancer therapy, although clinical drugs specifically directed at IER5L remain unknown.

Other names

IER5LbA247A12.2